First-in-Human<sup>212</sup>Pb-PSMA–Targeted α-Therapy SPECT/CT Imaging in a Patient with Metastatic Castration-Resistant Prostate Cancer
Matthew R. Griffiths, David A. Pattison, Melissa J. Latter, Kevin Kuan, Stephen Taylor, William Tieu, Thomas Kryza, Danielle Meyrick, B. Q. Lee, Aaron R. Hansen, Stephen Rose, Simon Puttick
Abstract
There is significant interest in the development of 212Pb-PSMA–based targeted α-therapy for patients with metastatic castration-resistant prostate cancer. A previous phantom study has shown that 212Pb SPECT is feasible by imaging the 238.6 keV and 75 to 91 keV γ-emissions produced after the β-
Topics & Concepts
Prostate cancerMedicineCastrationSpect imagingOncologyCancer imagingPet imagingNuclear medicineCancerPositron emission tomographyInternal medicineHormoneProstate Cancer Treatment and ResearchRadiomics and Machine Learning in Medical ImagingRadiopharmaceutical Chemistry and Applications